June 19, 2023 News by Andrea Lobo, PhD Potential blood biomarker of Gilenya response found in MS patients A microRNA called miR-548a-3p, a small molecule important for regulation of gene activity, may help to identify people with multiple sclerosis (MS) who will reach no evidence of disease activity ā a status known as NEDA-3 ā after treatment with Gilenya (fingolimod), a study found. Data showed that…
June 28, 2022 News by Marisa Wexler, MS No Disease Activity After 4 Years for Nearly 80% of Patients on Kesimpta People with relapsing forms of multiple sclerosis (MS) who were continuously on Kesimpta (ofatumumab) for up to four years were about four times more likely to have no evidence of disease activity than those initially on Aubagio (teriflunomide), according to updated data from the ASCLEPIOS and ALITHIOS…
June 7, 2022 News by Marisa Wexler, MS No Disease Activity for 58% of Those on Aubagio After 2 Years: Study More than half of the people with multiple sclerosis (MS) treated withĀ Aubagio (teriflunomide) showed no evidence of disease activity after two years on treatment, according to aĀ study in Italy. The study, “Evolution of teriflunomide use in multiple sclerosis: A real-world experience,” was published in theĀ Journal of…
July 24, 2017 News by Patricia Inacio, PhD Study Draws Reverse Link Between Number of a Patientās MRI Scans a Doctor Checks and Worsened-MS Declarations A new study draws a reverse link between the number of MRI scans of multiple sclerosis patients who are on interferon-beta 1a and doctors declaring there is evidence of the patients’ disease worsening. When doctors looked at one scan, rather than multiple ones, they were more likely to say that…
February 23, 2017 News by Patricia Inacio, PhD #ACTRIMS2017 – Lemtrada Maintains Durable Positive Effects in MS Without Additional Treatment Two Phase 3 clinical trials investigating the long-term effects of Lemtrada (alemtuzumab) in multiple sclerosis (MS) patients showed the drug maintained improved outcomes, even in the absence of further treatment. Both studies were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum, held…
August 11, 2016 News by Patricia Silva, PhD Early Disease Activity in MS Seen to Have Little Long-Term, Prognostic Value A large study of multiple sclerosis patients (MS) came to the conclusion that clinical and brain imaging assessments drawn from magnetic resonance imaging (MRI) scansĀ areĀ poor measures of long-term prognosis for patients. The study, āLong-term evolution of multiple sclerosis disability in the treatment era,ā published in the journal…
December 26, 2014 News by admin Long-Term Multiple Sclerosis Progress Can Be Better Determined Using NEDA Standard A study published on December 22 in JAMA Neurology emphasizes that a standard measurement used to gauge multiple sclerosis (MS) symptoms, known as “no-evidence-of-disease-activity” (NEDA) is important for determining how the disease will progress long-term. MS is the most common degenerative neurological condition that affects young adults worldwide.